Type 2 diabetes (T2D) is a complex chronic disease characterized by considerable phenotypic heterogeneity. year of T2D diagnosis and drug use as covariates in the model. To assess the time to
More recently, new drugs in different classes have been approved to treat Type 2 diabetes (T2D) and many others are being developed . In this report, we will review the latest developments in the pharmacology of using T2D drugs to treat T1D.
In T2D patients, treatment with metformin is associated with reduced blood Mg2 levels. To investigate how T2D and metformin affect Mg2 homeostasis db/m and db
GIP receptor agonist, are contraindicated. T2D: Real Benefits of New Oral Antidiabetic Drugs.
1 Medicines to treat T2D, including insluin therapy and other medications, have dramatically improved both the length and quality of life for people with T2D
Type 2 diabetes (T2D) has a continuously rising prevalence worldwide. Pharmacogenetics has been recognized as a promising concept for pharmacological treatment of T2D, as antidiabetic drugs are not equally effective and safe for all patients, and the costs of diabetes treatment are increasing.
Chronic kidney disease (CKD), a serious complication of T2D that affects between 25% and 40% of all patients with T2D, is characterized by
Chronic kidney disease (CKD), a serious complication of T2D that affects between 25% and 40% of all patients with T2D, is characterized by
The exhaustive list of pathophysiologic mechanisms that contribute to T2D is matched by an equally notable array of evidence-based drugs and drug combinations.
Comments